Analysts Set Expectations for Immatics FY2026 Earnings

Immatics (NASDAQ:IMTX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Immatics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($1.50) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $20.12 million for the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%.

A number of other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immatics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Immatics has a consensus rating of "Moderate Buy" and a consensus target price of $14.67.

Immatics Price Performance

IMTX stock traded down $0.06 during trading on Tuesday, hitting $5.94. 494,095 shares of the company traded hands, compared to its average volume of 649,105. The company has a market cap of $722.01 million, a PE ratio of -9.00 and a beta of 0.83. The stock's 50-day simple moving average is $4.72 and its 200 day simple moving average is $5.47. Immatics has a 1 year low of $3.30 and a 1 year high of $13.69.

Institutional Investors Weigh In On Immatics

A number of institutional investors have recently added to or reduced their stakes in IMTX. Vestal Point Capital LP lifted its holdings in Immatics by 14.6% during the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock valued at $32,439,000 after purchasing an additional 917,700 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Immatics during the first quarter worth about $783,000. Pale Fire Capital SE raised its position in shares of Immatics by 8.9% during the 1st quarter. Pale Fire Capital SE now owns 34,270 shares of the company's stock worth $155,000 after purchasing an additional 2,808 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Immatics by 38.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock valued at $66,194,000 after buying an additional 4,072,226 shares in the last quarter. Finally, Algert Global LLC lifted its stake in Immatics by 20.6% in the 1st quarter. Algert Global LLC now owns 70,668 shares of the company's stock valued at $319,000 after buying an additional 12,072 shares in the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.